Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight

NCT05726227 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05726227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05726227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 7, 2023
Completion date
December 7, 2026
Enrollment
212 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

obesity